CAS: 1202400-18-7
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | BMS-817399 REF: 54-BUP12300CAS: 1202400-18-7 | ≥98% | 1,191.00 €~4,927.00 € | Wed 30 Apr 25 |
 | BMS-817399 REF: TM-T26861CAS: 1202400-18-7 | 99.05% | 160.00 €~3,517.00 € | Tue 17 Jun 25 |
Ref: 54-BUP12300
| 1g | 4,927.00 € | ||
| 25mg | 1,191.00 € | ||
| 50mg | 1,479.00 € | ||
| 100mg | 1,993.00 € | ||
| 500mg | 3,501.00 € |
Estimated delivery in United States, on Wednesday 30 Apr 2025
BMS-817399
CAS:1202400-18-7
BMS-817399: oral CCR1 antagonist with binding and chemotaxis inhibition IC50s, potential for rheumatoid arthritis research.
Formula:
C23H36ClN3O4
Purity:
99.05%
Color and Shape:
Solid
Molecular weight:
454
Ref: TM-T26861
| 1mg | 160.00 € | ||
| 5mg | 338.00 € | ||
| 10mg | 512.00 € | ||
| 25mg | 812.00 € | ||
| 50mg | 1,093.00 € | ||
| 100mg | 1,473.00 € | ||
| 1mL*10mM (DMSO) | 376.00 € |
Estimated delivery in United States, on Tuesday 17 Jun 2025
